1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1/2 study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer
    Meeting Abstract

    Van Nieuwenhuysen, E.; Bouberhan, S.; Papadimitriou, K.; Arend, R. C.; Lee, J. Y.; O'Cearbhaill, R. E.; O'Malley, D. M.; You, B.; Martin, A. G.; Michels, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Khawaja, Mrruh; Naqash, A. R.; Schneider, R.; Shastri, A.; Stahl, M.; Moser, J. C.; Karim, N. F. A.; Madanat, Y.; Jonas, B. A.; Stein, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies
    Meeting Abstract

    Park, Y. H.; Cortes, J.; Modi, S.; Hurvitz, S. A.; Bianchini, G.; Iwata, H.; Shitara, K.; Siena, S.; Goto, Y.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP)
    Meeting Abstract

    Till, B. G.; Jacobson, C. A.; Palomba, M. L.; Abramson, J. S.; Arnason, J.; Locke, F. L.; Caimi, P. F.; Grover, N. S.; Karmali, R.; Suh, H. C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Epcoritamab with rituximab + lenalidomide (R(2)) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7
    Meeting Abstract

    Lori, L. A.; Falchi, L.; Vermaat, J. S. P.; Musuraca, G.; Belada, D.; Nijland, M.; Christensen, J. H.; Offner, F.; Hoehn, D.; Marek, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study
    Meeting Abstract

    Lue, J. K.; Morschhauser, F.; Tilly, H.; Lenz, G.; Jardin, F.; Herrera, A. F.; Sharman, J. P.; Flowers, C.; Friedberg, J. W.; Trneny, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation
    Meeting Abstract

    Al Malki, M. M.; Bo-Subait, S.; Logan, B.; Olson, J.; Leckrone, E.; Wu, J.; Stefanski, H. E.; Auletta, J. J.; Spellman, S. R.; Malmberg, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
    Meeting Abstract

    Mitchell, S.; Khan, B.; Payumo, F.; Chiorean, E. G.; Gahvari, Z.; Hecht, J. R.; Hurwitz, M. E.; Leidner, R.; Lenz, H. J.; Pelster, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade
    Meeting Abstract

    Ricciuti, B.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Citarella, F.; Gandhi, M. M.; Elkrief, A.; Pecci, F.; Alessi, J. V. M.; Di Federico, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup
    Meeting Abstract

    Cohen, A. D.; Voorhees, P. M.; Martin, T. G.; Lesokhin, A. M.; Hillengass, J.; Kaufman, J. L.; Schecter, J. M.; De Braganca, K. C.; Varsos, H.; Corsale, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save